Daraxonrasib Shows Meaningful Survival Benefit in Advanced Pancreatic Cancer: What Oncologists and Patients Should Know
Oncologist Dr. Avishek Kumar explains why daraxonrasib — showing 13.2 vs 6.7 months median survival in advanced pancreatic cancer — may signal a turning point in treating this difficult disease....
05 June, 2026